Eletis Pharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,347,318 | 1,964,409 | 2,181,360 | 943,203 | 1,643,413 | 1,983,138 | 1,611,465 | 1,598,653 |
| Profit before tax | - | - | 22,318 | -54,579 | 8,804 | 27,734 | 32,487 | 9,924 |
| Net profit | 10,038 | 26,512 | 16,629 | -54,579 | 8,165 | 25,896 | 29,747 | 7,770 |
| Equity | 15,750 | 42,262 | 58,891 | 4,312 | 12,477 | 38,372 | 68,119 | 75,889 |
| Liabilities | 194,994 | 392,663 | 275,685 | 233,729 | 268,291 | 293,553 | 398,514 | 364,539 |
| Non-current assets | 184 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Current assets | 210,560 | 434,924 | 334,575 | 238,040 | 280,767 | 331,924 | 466,632 | 440,427 |
| Total assets | 210,744 | 434,925 | 334,576 | 238,041 | 280,768 | 331,925 | 466,633 | 440,428 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 167,397 | 152,964 | 81,418 |
| Social insurance contributions | - | - | - | - | - | 12,585 | 14,304 | 14,979 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +28.8% | +45.8% | +11.0% | -56.8% | +74.2% | +20.7% | -18.7% | -0.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 4.8% | 6.1% | 5.0% | -22.9% | 2.9% | 7.8% | 6.4% | 1.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 63.7% | 62.7% | 28.2% | -1265.7% | 65.4% | 67.5% | 43.7% | 10.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 0.7% | 1.3% | 0.8% | -5.8% | 0.5% | 1.3% | 1.8% | 0.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | 1.0% | -5.8% | 0.5% | 1.4% | 2.0% | 0.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 12.4 | 9.3 | 4.7 | 54.2 | 21.5 | 7.7 | 5.9 | 4.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 404,199 | 654,803 | 727,120 | 290,216 | 410,853 | 495,785 | 402,866 | 361,956 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Eletis Pharma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-01-16 | 2026-02-09 | 0.23 |
| 2026-01-01 | 2026-01-12 | 0.23 |
| 2025-12-16 | 2025-12-30 | 0.23 |
| 2025-11-18 | 2025-12-10 | 0.23 |
| 2025-10-16 | 2025-11-09 | 0.23 |
| 2025-09-16 | 2025-10-12 | 0.23 |
| 2025-07-16 | 2025-08-06 | 0.23 |
| 2025-06-17 | 2025-07-09 | 0.23 |
| 2025-06-08 | 2025-06-08 | 0.23 |
| 2025-05-16 | 2025-06-04 | 0.23 |
| 2025-05-04 | 2025-05-04 | 0.23 |
| 2025-04-16 | 2025-04-30 | 0.23 |
| 2025-03-18 | 2025-04-03 | 0.23 |
| 2025-02-18 | 2025-03-05 | 0.23 |
| 2025-02-10 | 2025-02-10 | 0.23 |
| 2025-01-16 | 2025-02-06 | 0.23 |
| 2025-01-02 | 2025-01-08 | 0.23 |
| 2024-12-22 | 2024-12-31 | 0.23 |
| 2024-12-17 | 2024-12-20 | 0.23 |
| 2024-11-18 | 2024-12-09 | 0.23 |
| 2024-10-16 | 2024-11-10 | 0.23 |
| 2024-09-17 | 2024-10-02 | 0.23 |
| 2024-06-18 | 2024-07-10 | 0.23 |
| 2024-04-23 | 2024-05-08 | 0.23 |
| 2024-03-18 | 2024-03-24 | 76.79 |
| 2023-07-18 | 2023-08-09 | 3.32 |
| 2023-06-16 | 2023-07-09 | 3.32 |
| 2023-05-16 | 2023-06-05 | 3.32 |
| 2023-05-02 | 2023-05-10 | 3.32 |
| 2023-04-27 | 2023-04-28 | 3.32 |
| 2023-04-25 | 2023-04-25 | 3.32 |
| 2023-02-17 | 2023-02-23 | 1241.86 |
Eletis Pharma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Eletis Pharma, UAB (code 303572397) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €1.60M, slightly below €1.61M in 2024 and down from €1.98M in 2023, indicating a two-year decline in turnover. Net profit also weakened in 2025 to €7.8K from €29.7K in 2024 and €25.9K in 2023, while the net profit margin fell to 0.5% from 1.8% and 1.3% in the prior two years. Despite the lower profitability, equity increased to €75.9K in 2025 from €68.1K in 2024 and €38.4K in 2023. Total assets stood at €440.4K, compared with €466.6K in 2024 and €331.9K in 2023, while liabilities were €364.5K in 2025. The latest ratios show ROE at 10.2%, ROA at 1.8%, debt-to-equity at 4.80, and asset turnover at 3.63x. Revenue per employee reached €399.7K, with profit per employee at €1.9K.